Name: Actinogen Medical (ACW) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ACW

Pharmaceuticals, Biotechnology & Life Sciences

Actinogen Medical

Short interest: 0.00%; 0.00 pp 30d; as of 9 Oct 2026
Reported shorts: 15.9K
Shares on issue: 3.874B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Actinogen Medical

Actinogen Medical Limited focuses on the development and commercialization of novel therapeutic compounds, specifically targeting central nervous system diseases. Positioned as an innovative player in the biotechnology sector, Actinogen's flagship product, Xanamem, aims to treat Alzheimer's Disease and other neurodegenerative conditions, offering a unique therapeutic approach in a growing market. Their commitment to addressing unmet medical needs through rigorous clinical trials sets them apart from traditional pharmaceutical providers.

Company profile →

Actinogen Medical (ASX:ACW) has 0.00% of its shares on issue reported as short positions as of 9 Oct 2026, or about 15,940 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.19% in April 2015. ACW is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ACW today

Zanger BreakoutWatchScore 13rank 1564 of 1942
CAN SLIMWatchScore 21rank 628 of 1541
Minervini Trend TemplateWatchScore 25rank 694 of 1716
Crowded-Short BreakoutWatchScore 17rank 493 of 1500
Quality compoundersWatchScore 31rank 392 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ACW fundamentals

In the year to 30 Jun 2026, Actinogen Medical (ASX:ACW) recorded revenue of A$499.9K and a net loss after tax of A$15.4M. A year earlier it recorded revenue of A$685.3K and a net loss after tax of A$14.7M. Year-on-year growth: revenue −27.1% (FY). Net margin −3,076.8%, return on equity −77.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →